Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.

Autor:	Varadarajan I; Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, United States., Ballen K; Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Feb 11; Vol. 12, pp. 781479. Date of Electronic Publication: 2022 Feb 11 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.781479
Abstrakt:	T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative therapy in eligible patients. However, allogeneic stem cell transplant is also complicated by increased rates of infections from chemotherapy, acute graft-versus-host disease (GVHD), and chronic GVHD. This review aims to report the available literature on the efficacy and complications of consolidative HSCT. It also discusses the importance of patient selection and pre- and post-transplant complications including atypical infections and GVHD. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Varadarajan and Ballen.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu